Search

Your search keyword '"van der Hout, Annemieke H."' showing total 47 results

Search Constraints

Start Over You searched for: Author "van der Hout, Annemieke H." Remove constraint Author: "van der Hout, Annemieke H."
47 results on '"van der Hout, Annemieke H."'

Search Results

1. Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families

2. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

3. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

4. Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

7. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

8. Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset

11. Correction:PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients (Breast Cancer Research, (2022), 24, 1, (69), 10.1186/s13058-022-01567-3)

12. The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

13. 2022-RA-637-ESGO Five-year universal tumor screening ofBRCA1/2in epithelial ovarian carcinoma;is histotype-directed hr-deficiency testing justified?

15. PredictCBC-2.0:a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

16. Additional file 1 of PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

18. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

19. National external quality assessment for next-generation sequencing-based diagnostics of primary immunodeficiencies

21. Cancer risks for other sites in addition to breast in CHEK2c.1100delC families

22. National external quality assessment for next-generation sequencing-based diagnostics of primary immunodeficiencies

23. Families with BAP1-Tumor Predisposition Syndrome in The Netherlands : Path to Identification and a Proposal for Genetic Screening Guidelines

24. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

25. Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines

26. Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines

28. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

32. Phenotypic characterization of patients with deletions in the 3’-flanking SHOXregion

34. An urgent need for a change in policy revealed by a study on prenatal testing for Duchenne muscular dystrophy.

35. Possible Bradycardic Mode of Death and Successful Pacemaker Treatment in a Large Family with Features of Long QT Syndrome Type 3 and Brugada Syndrome.

36. The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

37. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

38. Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk

39. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

40. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

41. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

42. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

43. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

44. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

45. Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset.

46. Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families.

47. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.

Catalog

Books, media, physical & digital resources